GLP-1, GIP and glucagon: three receptors, and three peptides that now target them in every combination researchers care about. Semaglutide activates one receptor. Tirzepatide activates two. Retatrutide activates all three. That is not a marketing ladder. It changes what each peptide does inside a plate or an animal model, and it changes which one belongs in your protocol.
This guide compares the three most requested compounds in European research supply, Semaglutide, Tirzepatide and Retatrutide, across mechanism, assay behaviour and handling.
The incretin system in brief
Incretins are gut hormones released after eating that boost insulin secretion. Two dominate the literature: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). A third receptor, glucagon, was long treated as the counter-regulatory opposite: a hormone that raises glucose instead of lowering it.
Modern peptide engineering rewrote that assumption. Combine the receptor activities in one backbone, and you can model complementary pathways at the same time instead of isolating them one by one.
Semaglutide: the single-agonist benchmark
Semaglutide is still the reference point other molecules get measured against. As a selective GLP-1 receptor agonist, it produces well-characterised insulinotropic signalling, which is exactly why it works as the control arm in comparative studies.
The assay caveat: receptor desensitization
Anyone running in vitro metabolic assays with GLP-1 agonists has run into this: receptor desensitization can wreck a dataset. Repeated exposure in cellular models often drives rapid internalisation of the GLP-1 receptor. Once that happens, the signalling cascade no longer reflects the compound. It reflects a downregulated system.
- Keep baseline exposure conservative when profiling long-term signalling
- Allow recovery intervals between exposures in repeat-exposure models
- Treat unexpected signal decay as a receptor-availability question before assuming compound degradation
Tirzepatide: dual agonism at GIP and GLP-1
Tirzepatide combines GIP and GLP-1 receptor activation in a single synthetic sequence. The interesting part is what that does to adipocyte signalling.
Why does dual activation outperform single-receptor binding in lipolytic assays? Because the two pathways are complementary, not redundant. GLP-1 activation drives the same insulinotropic signalling seen with Semaglutide. GIP receptor engagement adds a separate layer of adipose tissue response on top of it. Combining both in one molecule also removes a practical confounder: dosing two separate peptides together means juggling two different stability and clearance profiles in the same well.
Retatrutide: tri-agonism and the glucagon arm
Retatrutide adds a third receptor: glucagon. That is the step that separates it from earlier incretin mimetics.
In hepatocyte research models, selective glucagon receptor binding stimulates cAMP and PKA pathways that drive hepatic lipolysis and beta-oxidation. On its own, that activity would raise glucose. Paired with GIP and GLP-1 agonism, the insulinotropic action counterbalances it. That balance is exactly why the tri-agonist design gets attention in hepatic steatosis and adipose oxidation models.
For labs modelling complex metabolic states, the appeal is simple: one engineered backbone reproduces a multi-pathway condition that used to need a cocktail of separate compounds.
Side by side
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Receptors | GLP-1 | GIP + GLP-1 | GIP + GLP-1 + glucagon |
| Generation | Single-agonist | Dual-agonist | Tri-agonist |
| Typical research use | Benchmark and control arm | Adipocyte and insulinotropic synergy | Hepatic fat clearance, complex metabolic models |
| Key assay consideration | Receptor desensitization | Pathway attribution between GIP and GLP-1 | Glucose counter-balance between arms |
Handling: where good data is won or lost
Mechanism means little if the peptide degrades before it reaches the plate. Three things matter more than any theory.
Lyophilisation and structural integrity. Multi-agonist peptides have more complex secondary structure than single-target molecules, so they are more sensitive to freeze-thaw stress and aggregation. Treat reconstituted material as a finite-life reagent, not a stock chemical.
Thermal exposure in transit. Peptides shipped intercontinentally pick up thermal load before anyone even opens the vial, a variable no assay design can correct for afterwards. Sourcing from within the EU shortens that exposure window considerably.
Verification before use. Purity is a measurement, not a marketing claim. Every batch we supply is third-party tested. If you cannot pull a certificate for the exact batch sitting in your freezer, you cannot defend the dataset built on it.
Which one for which model?
- Establishing a baseline or replicating published GLP-1 work: Semaglutide, with desensitization controls built into the design
- Investigating GIP contribution or adipocyte-level synergy: Tirzepatide, ideally alongside a Semaglutide arm for attribution
- Modelling hepatic fat clearance or multi-pathway metabolic states: Retatrutide, where the glucagon arm is the variable of interest
Most comparative programmes end up running at least two of the three. If that applies to your work, the Retatrutide Complete Kit bundles the vial with bacteriostatic water, syringes and prep pads so reconstitution conditions stay consistent across arms. The full range of single vials and multi-size options is in the catalogue.
All products supplied by Pepsup are for laboratory research use only. Not for human or veterinary consumption, and not for diagnostic or therapeutic use.